Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease - PubMed
2 days ago
- #Alzheimer's disease
- #donanemab
- #infusion-related reactions
- Infusion-related reactions (IRRs) are common in donanemab-treated participants with early symptomatic Alzheimer's disease (AD).
- 8.3% of 2727 participants reported IRRs, with 56.5% mild and 38.4% moderate in severity.
- Most IRRs occurred during or within 30 minutes after infusion, with 77% of participants experiencing their first IRR by the fourth infusion.
- Common symptoms included nausea/vomiting (3.5%), chills (3.3%), and erythema (3.1%).
- Elevated tryptase levels were observed in 37.9% of participants with IRRs, correlating with moderate severity.
- 65.1% of participants with prior IRRs tolerated rechallenge infusions, though prophylaxis medication did not reduce IRR risk.
- Previous drug allergy and anaphylaxis were significant predictors of IRRs (p < 0.01).
- Serious IRRs and anaphylaxis were reported, though most reactions were mild to moderate.